tiprankstipranks
Trending News
More News >

Isofol Medical’s Rights Issue Fully Subscribed, Boosting Financial Position

Story Highlights
Isofol Medical’s Rights Issue Fully Subscribed, Boosting Financial Position

Don’t Miss TipRanks’ Half-Year Sale

An announcement from Isofol Medical AB ( (SE:ISOFOL) ) is now available.

Isofol Medical AB announced that its rights issue was fully subscribed, raising approximately SEK 91 million before costs. The oversubscription allowed the company to allocate shares to its Japanese partner, Solasia Pharma K.K., strengthening its financial position and supporting its strategy to generate new clinical data for arfolitixorin, which is expected to enhance cancer treatment options.

More about Isofol Medical AB

Isofol Medical AB is a biotechnology company based in Gothenburg, Sweden, focusing on developing treatments for cancer patients. The company’s primary product is arfolitixorin, a drug aimed at improving the treatment outcomes for cancer patients worldwide.

Average Trading Volume: 839,451

Current Market Cap: SEK237.6M

For a thorough assessment of ISOFOL stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1